All In Biotech

Drug Trial Radar · NCT04599855

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 477 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

477

Actual

Start

Nov 4, 2020

Primary completion

Jan 31, 2024

Study completion Jan 31, 2024

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

  • Esketamine 56 mgDrug

    Esketamine 56 mg will be self administered as nasal spray.

  • Esketamine 84 mgDrug

    Esketamine 84 mg will be self administered as nasal spray.

  • PlaceboDrug

    Matching placebo will be self administered as nasal spray.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28Time frame: Day 1 (pre-randomization) to Day 28 (end of DB treatment phase)

Locations

54 sites in 1 country. Site status is shown where the registry gives one.

  • UAB Department of Psychiatry and Behavioral Neurobiology

    Birmingham, Alabama

  • UAB Huntsville Regional Medical Campus

    Huntsville, Alabama

  • Preferred Research Partners

    Little Rock, Arkansas

  • Behavioral Research Specialists LLC

    Glendale, California

  • CalNeuro Research

    Los Angeles, California

  • Pacific Research Partners

    Oakland, California

  • Anderson Clinical Research

    Redlands, California

  • University of California at San Diego

    San Diego, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • UCSF Nancy Friend Pritzker Psychiatry Building

    San Francisco, California

  • Velocity Clinical Research

    Santa Ana, California

  • CMB Clinical Trials

    Santee, California

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida

  • Accel Research Sites

    Lakeland, Florida

  • APG Research LLC

    Orlando, Florida

  • USF, Department of Psychiatry and Behavioral Neurosciences

    Tampa, Florida

  • Neuroscience Research Institute

    West Palm Beach, Florida

  • Atlanta Behavioral Research, LLC

    Atlanta, Georgia

  • Psych Atlanta, P.C.

    Marietta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Chicago Research Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Joliet Center for Clinical Research

    Joliet, Illinois

  • Pillar Clinical Research, LLC

    Lincolnwood, Illinois

  • Psychiatric Medicine Associates LLC

    Skokie, Illinois

  • Ascension via Christi Research

    Wichita, Kansas

  • University of Kansas School of Medicine

    Wichita, Kansas

  • Sheppard Pratt Health System

    Baltimore, Maryland

  • CBH Health

    Gaithersburg, Maryland

  • Copley Clinical

    Boston, Massachusetts

  • Adams Clinical

    Watertown, Massachusetts

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Rochester Center for Behavioral Medicine (RCBM)

    Rochester Hills, Michigan

  • Midwest Research Group - St. Charles Psychiatric Associates

    Saint Charles, Missouri

  • Clinilabs

    New York, New York

  • The Medical Research Network, LLC

    New York, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • Ohio State University

    Columbus, Ohio

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.